We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

Prone Positioning Not Relevant to Survival Rate in Patients with ARDS

By HospiMedica International staff writers
Posted on 30 Nov 2009
Prone positioning during mechanical ventilation may not improve survival duration in patients with acute respiratory distress syndrome (ARDS), according to a new study.

Researchers at the Ospedale Maggiore Policlinico di Milano (Italy) conducted the multicenter randomized Prone-Supine II trial to evaluate possible outcome benefits of prone positioning in patients with ARDS and moderate or severe hypoxemia. A total of 342 adults with ARDS receiving mechanical ventilation at 23 centers in Italy, and two in Spain, were enrolled in the study, and were prospectively stratified into subgroups with moderate and severe hypoxemia. The participants were randomly selected to supine positioning (174 patients) or prone positioning for 20 hours per day (168 patients) during ventilation. The main endpoint of the study was 28-day all-cause mortality, and secondary endpoints were 6-month mortality and mortality at intensive care unit discharge, organ dysfunction, and complication rate associated with prone positioning.

The researchers found that for the overall entire study population evaluated between February 2004 and June 2008, prone and supine positioning were associated with similar mortality rates at 28 days and six months; however, the prone group had a significantly higher complication rate. For patients with moderate hypoxemia, outcomes were also similar in the prone and supine groups at 28 days and at 6 months. For patients with severe hypoxemia, 28-day mortality rate was 37.8% in the prone group and 46.1% in the supine group, and six-month mortality rate was 52.7% and 63.2%, respectively. Positioning was not associated with any apparent differences in median sequential organ failure assessment (SOFA) scores, ventilator-free days, or intensive care unit length of stay. The study was published in the November 11, 2009, issue of the Journal of the American Medical Association (JAMA).

"Do the findings of this trial, together with those of previous studies, represent the end of the prone position technique?” inquired lead author Paolo Taccone, M.D., and colleagues of the department of anesthesia. "Undoubtedly, the data of the present trial together with previous results clearly indicate that prolonged prone positioning, in the unselected ARDS population, is not indicated as a treatment. However, its potential role in patients with the most severe hypoxemia, for whom the possible benefit could outweigh the risk of complications, must be further investigated.”

Related Links:

Ospedale Maggiore Policlinico di Milano



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical System
Stealth AXiS
Gas Analyzer
GE SAM

Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more